SF
TGTX icon

Symphony Financial’s TG Therapeutics TGTX Stock Holding History

Symphony Financial’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,003
Closed -$406K – 312
2025
Q3 		$406K Buy
11,003
+3
+0% +$99 0.05% 181
2025
Q2 		$399K Hold
11,000
– – 0.05% 176
2025
Q1 		$425K Hold
11,000
– – 0.25% 67
2024
Q4 		$324K Buy
+11,000
New +$316K 0.05% 168
2024
Q3 		– Sell
-11,000
Closed -$198K – 237
2024
Q2 		$198K Buy
+11,000
New +$176K 0.04% 203
2024
Q1 		– Sell
-11,000
Closed -$220K – 207
2023
Q4 		$220K Hold
11,000
– – 0.05% 183
2023
Q3 		$87.6K Hold
11,000
– – 0.02% 156
2023
Q2 		$279K Buy
+11,000
New +$284K 0.07% 158

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Symphony Financial's TGTX Position: Q4 2025 in Review

Symphony Financial sold out of TG Therapeutics (TGTX) in Q4 2025, closing a stake of 11,003 shares — an estimated $406K sold.

Symphony Financial first reported a position in TGTX in Q2 2023 and held it in 8 quarters. The position peaked at $425K in Q1 2025. 352 funds tracked by Wall St. Rank hold TGTX as of Q4 2025.

  • Symphony Financial reported no remaining TG Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Symphony Financial sold 11,003 TG Therapeutics shares in Q4 2025, an estimated $406K.
  • Symphony Financial first reported a position in TG Therapeutics in Q2 2023 and held it in 8 quarters.
  • Symphony Financial's TG Therapeutics position peaked at $425K in Q1 2025.
  • 352 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2025.

Based on Symphony Financial's 13F filing for Q4 2025, filed 11 Feb 2026.